Taking stock of the drug industry, from the lab to the medicine chestMay 6, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer David L Ryan/Globe Staff Opinion: How to stop the shift of drug discovery from the U.S. to China U.S. drug firms license compounds from China due to lower costs, faster trials. Former FDA commissioner says regulatory reform needed to stay competitive. By Scott Gottlieb STAT+ | Few drugmakers embrace a newer test for contamination, placing horseshoe crabs at risk The pharmaceutical industry has long relied on a test that uses a protein called LAL taken from the blood of American horseshoe crabs. By Ed Silverman STAT+ | Vinay Prasad tapped to run FDA center that regulates vaccines, gene therapies Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was forced out. By Lizzy Lawrence, Jason Mast, and Matthew Herper Anna Moneymaker/Getty Images STAT+ | Trump signs order in bid to boost pharma manufacturing in the U.S. Federal agencies, including the FDA and the EPA, were ordered to accelerate approval of domestic manufacturing plants. By Ed Silverman STAT+ | Vertex reports an earnings miss and pause on cystic fibrosis trial Vertex shares fell in after-hours trading, as investors considered a stock trading near its high with a wait for its next leg of growth. By Adam Feuerstein and Jason Mast More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments